Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
AQST
Aquestive Therapeutics
$6.54
Login to see Aquestive Therapeutics (AQST) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Outperform the market
Chart
$4.87 (+34.29%)
$4.23 (+54.61%)
$2.27 (+188.11%)
$5.49 (+19.13%)
AQST has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
AQST overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
AQST Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AQST Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayAQST Earnings
The TTM reflects 12-month period, providing review of AQST financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is AQST current stock price?
What are AQST stock strengths?
What risks are associated with AQST stock?
When is AQST next earnings report?
What is AQST market cap and volume?
What is AQST's current Stock IQ?
Should I buy AQST stock right now?
Is AQST a Strong Buy right now?
What does a 'Strong Buy' rating mean for AQST?
What does a 'Strong Sell' rating mean for AQST?
What factors influence AQST's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
AQST
Aquestive Therapeutics
Current Price
$6.54
Stock Insights
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Outperform the market
Login to unlock Aquestive Therapeutics (AQST) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$4.87 (+34.29%)
$4.23 (+54.61%)
$2.27 (+188.11%)
$5.49 (+19.13%)
AQST Analysts Opinion
AQST Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
AQST Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AQST Street view is extremely bullish and have positive views on the near-term outlook
AQST has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
Average key support and resistance price levels.
Login to displayAQST Earnings
The TTM data reflects the most recent 12-month period, providing overview of AQST financial performance.
AQST Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
AQST Latest Analysis
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?. Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Fri Oct 10, 2025
JMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform Recommendation. Fintel reports that on October 9 2025 JMP Securities maintained coverage of Aquestive Therapeutics (NasdaqGM:AQST) with a Market Outperform recommendation. Analyst Price Forecast Suggests 44.36% Upside
Thu Oct 9, 2025
Aquestive gains after new patent wins for Anaphylm.
Wed Oct 8, 2025
Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?. Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Mon Sep 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AQST Stock trends
AQST Stock performance
AQST Stock analysis
AQST investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders